Brightfield Group Q2 Report: The GLP-1/Ozempic Craze

This report, which focuses on the GLP/Ozempic craze, features exclusive content created just for our Nosh Insider audience! Please note that below is a shortened excerpt of the report. View the full version here.

The numbers don’t lie: Over half of Americans are actively trying to shed pounds. The U.S. faces a weight problem with obesity rates more than doubling since 1980 and remaining stubbornly high for over two decades. A staggering 69% of adults are classified as overweight or obese, according to the Journal of American Medical Association, with a concerning 36% falling into the obese category. Our data shows no signs of slowing down: overweight individuals in our panel data have increased by 5.4% year-over-year since 2022. Social listening paints a similar picture, with conversations about being overweight experiencing a whopping 50.1% growth in social engagement. This surge suggests a growing public desire to address weight concerns and a burning desire for change.

Close to 3-5% of the general population have been using semaglutide injections for weight management over the past year, a rate comparable to products like oat milk lattes and matcha tea! While recent growth in semaglutide use has slowed, there are indications of another surge. Interest in social media and innovation in GLP-1 products is on the rise, as are product innovations within the industry. Could we see another surge in GLP-1 use by January 2025? Brightfield Group’s data suggests it’s possible, driven by increased consumer interest and new product development.